ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SBFM Sunshine Biopharma Inc

0.92
0.03 (3.37%)
May 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,037,246
Bid Price 0.92
Ask Price 0.9328
News -
Day High 1.00

Low
0.75

52 Week Range

High
67.01

Day Low 0.8804
Company Name Stock Ticker Symbol Market Type
Sunshine Biopharma Inc SBFM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 3.37% 0.92 19:59:31
Open Price Low Price High Price Close Price Prev Close
0.92 0.8804 1.00 0.93 0.89
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,381 4,037,246 $ 0.9433947 $ 3,808,716 - 0.75 - 67.01
Last Trade Time Type Quantity Stock Price Currency
19:59:55 formt 3,592 $ 0.92 USD

Sunshine Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
23.88M 25.68M - 24.09M -4.51M -0.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Sunshine Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SBFM Message Board. Create One! See More Posts on SBFM Message Board See More Message Board Posts

Historical SBFM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.90021.160.830.89437833,976,3070.01982.20%
1 Month2.342.450.751.027,517,105-1.42-60.68%
3 Months6.0514.250.757.7426,043,194-5.13-84.79%
6 Months27.0031.860.757.8113,237,041-26.08-96.59%
1 Year57.5067.010.758.336,623,368-56.58-98.40%
3 Years275.00987.000.75167.294,581,839-274.08-99.67%
5 Years275.00987.000.75167.294,581,839-274.08-99.67%

Sunshine Biopharma Description

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Your Recent History

Delayed Upgrade Clock